The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection
Related Experiment Video
Updated: Sep 28, 2025
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Lei Zhao1, Yunzheng Yan1, Qingsong Dai1
1National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Abstract:
Many viruses use the host cell division cycle to facilitate replication. Cyclin-dependent kinases (CDKs) are a group of serine/threonine kinases that play a central role in regulating cell cycle progression. However, the prospect of using CDKs for anti-influenza virus treatment remains to be elucidated. We conducted this study to investigate the potential of the CDK1 inhibitor Ro-3306 in preventing influenza virus infection and to elucidate the underlying mechanism. We showed that Ro-3306, a CDK1 inhibitor, exerts anti-influenza activity both in vitro and in vivo. Proof-of-concept studies revealed that knockdown of host CDK1 might affect the splicing of M2 viral mRNA, leading to the restriction of viral replication. Moreover, Ro-3306 directly bound to viral PB2 protein and inhibited viral RNA replication. Transcriptome analysis further revealed that Ro-3306 treatment inhibited the expression of MAPK-regulated genes, which might also contribute to the antiviral activity of Ro-3306. This study highlighted the multifunctional role of Ro-3306 as a novel anti-influenza virus agent.
Insights
The cyclin-dependent kinase 1 (CDK1) inhibitor Ro-3306 shows significant anti-influenza virus activity. This novel agent targets viral RNA replication and host cell processes, offering a new therapeutic strategy against influenza.
Area of Science:
- Virology
- Cell Biology
- Pharmacology
Background:
- Viruses exploit host cell division for replication.
- Cyclin-dependent kinases (CDKs) regulate the cell cycle.
- The antiviral potential of CDK inhibitors against influenza is underexplored.
Purpose of the Study:
- To investigate the efficacy of the CDK1 inhibitor Ro-3306 against influenza virus.
- To elucidate the mechanisms underlying Ro-3306's antiviral activity.
Main Methods:
- In vitro and in vivo influenza virus infection models.
- Host CDK1 knockdown experiments.
- Viral M2 mRNA splicing analysis.
- Ro-3306 binding assays with viral PB2 protein.
- Transcriptome analysis (RNA sequencing).
Main Results:
- Ro-3306 demonstrated anti-influenza activity in vitro and in vivo.
- CDK1 inhibition affected M2 viral mRNA splicing, restricting replication.
- Ro-3306 directly inhibited viral RNA replication by binding to PB2.
- Ro-3306 suppressed MAPK-regulated gene expression, contributing to antiviral effects.
Conclusions:
- Ro-3306 is a potent inhibitor of influenza virus replication.
- Ro-3306 exhibits multifaceted antiviral mechanisms, including direct viral targeting and host pathway modulation.
- Ro-3306 represents a promising novel therapeutic agent for influenza treatment.
More Related Videos
09:29Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15Experimental RNAi